319 related articles for article (PubMed ID: 30069760)
21. Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.
Schmidinger M; Danesi R
Oncologist; 2018 Mar; 23(3):306-315. PubMed ID: 29146618
[TBL] [Abstract][Full Text] [Related]
22. Cabozantinib in progressive medullary thyroid cancer.
Elisei R; Schlumberger MJ; Müller SP; Schöffski P; Brose MS; Shah MH; Licitra L; Jarzab B; Medvedev V; Kreissl MC; Niederle B; Cohen EE; Wirth LJ; Ali H; Hessel C; Yaron Y; Ball D; Nelkin B; Sherman SI
J Clin Oncol; 2013 Oct; 31(29):3639-46. PubMed ID: 24002501
[TBL] [Abstract][Full Text] [Related]
23. Cabozantinib: A Review in Advanced Renal Cell Carcinoma.
Al-Salama ZT; Keating GM
Drugs; 2016 Dec; 76(18):1771-1778. PubMed ID: 27909994
[TBL] [Abstract][Full Text] [Related]
24. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Sherman SI; Clary DO; Elisei R; Schlumberger MJ; Cohen EE; Schöffski P; Wirth LJ; Mangeshkar M; Aftab DT; Brose MS
Cancer; 2016 Dec; 122(24):3856-3864. PubMed ID: 27525386
[TBL] [Abstract][Full Text] [Related]
25. Cabozantinib: a review of its use in patients with medullary thyroid cancer.
Hoy SM
Drugs; 2014 Aug; 74(12):1435-44. PubMed ID: 25056653
[TBL] [Abstract][Full Text] [Related]
26. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Lin DW; Corey E; Nelson PS; Morrissey C
PLoS One; 2021; 16(1):e0245602. PubMed ID: 33471819
[TBL] [Abstract][Full Text] [Related]
27. Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor.
Markowitz JN; Fancher KM
Pharmacotherapy; 2018 Mar; 38(3):357-369. PubMed ID: 29283440
[TBL] [Abstract][Full Text] [Related]
28. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Choueiri TK; Escudier B; Powles T; Mainwaring PN; Rini BI; Donskov F; Hammers H; Hutson TE; Lee JL; Peltola K; Roth BJ; Bjarnason GA; Géczi L; Keam B; Maroto P; Heng DY; Schmidinger M; Kantoff PW; Borgman-Hagey A; Hessel C; Scheffold C; Schwab GM; Tannir NM; Motzer RJ;
N Engl J Med; 2015 Nov; 373(19):1814-23. PubMed ID: 26406150
[TBL] [Abstract][Full Text] [Related]
29. 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma.
Lin H; Jiang X; Zhu H; Jiang W; Dong X; Qiao H; Sun X; Jiang H
Tumour Biol; 2016 Jan; 37(1):381-91. PubMed ID: 26219898
[TBL] [Abstract][Full Text] [Related]
30. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
Schöffski P; Gordon M; Smith DC; Kurzrock R; Daud A; Vogelzang NJ; Lee Y; Scheffold C; Shapiro GI
Eur J Cancer; 2017 Nov; 86():296-304. PubMed ID: 29059635
[TBL] [Abstract][Full Text] [Related]
31. Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.
Scott AJ; Arcaroli JJ; Bagby SM; Yahn R; Huber KM; Serkova NJ; Nguyen A; Kim J; Thorburn A; Vogel J; Quackenbush KS; Capasso A; Schreiber A; Blatchford P; Klauck PJ; Pitts TM; Eckhardt SG; Messersmith WA
Mol Cancer Ther; 2018 Oct; 17(10):2112-2122. PubMed ID: 30026382
[TBL] [Abstract][Full Text] [Related]
32. Cabozantinib use in renal cell carcinoma.
Neuwelt AJ; Mathur S; Johnson AT; Kessler ER; Bowles DW
Drugs Today (Barc); 2017 May; 53(5):299-307. PubMed ID: 28650002
[TBL] [Abstract][Full Text] [Related]
33. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.
Belum VR; Serna-Tamayo C; Wu S; Lacouture ME
Clin Exp Dermatol; 2016 Jan; 41(1):8-15. PubMed ID: 26009777
[TBL] [Abstract][Full Text] [Related]
34. Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience.
Ruiz-Morales JM; Heng DY
Ther Adv Urol; 2016 Dec; 8(6):338-347. PubMed ID: 27904650
[TBL] [Abstract][Full Text] [Related]
35. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Zhang L; Scorsone K; Woodfield SE; Zage PE
Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819
[TBL] [Abstract][Full Text] [Related]
37. Cabozantinib for the treatment of hepatocellular carcinoma.
Personeni N; Rimassa L; Pressiani T; Smiroldo V; Santoro A
Expert Rev Anticancer Ther; 2019 Oct; 19(10):847-855. PubMed ID: 31603008
[No Abstract] [Full Text] [Related]
38. Cabozantinib as an emerging treatment for sarcoma.
Schöffski P; Blay JY; Ray-Coquard I
Curr Opin Oncol; 2020 Jul; 32(4):321-331. PubMed ID: 32541320
[TBL] [Abstract][Full Text] [Related]
39. ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of
Bagheri-Yarmand R; Dadu R; Ye L; Shiny Jebaraj Y; Martinez JA; Ma J; Tarapore RS; Allen JE; Sherman SI; Williams MD; Gagel RF
Mol Cancer Ther; 2021 Apr; 20(4):665-675. PubMed ID: 33536187
[TBL] [Abstract][Full Text] [Related]
40. Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
Schmidinger M; Motzer RJ; Rolland F; Staehler M; Rink M; Retz M; Csoszi T; McCaffrey JA; De Giorgi U; Caserta C; Duran I; Benzaghou F; Clary DO; Albiges L; Choueiri TK; Tannir NM
Acta Oncol; 2022 Jan; 61(1):52-57. PubMed ID: 34736367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]